Heli Dangur, Narkis Tessler
Aug 24, 2020 24 min

“Personalization Technology, Medicinal Mushrooms & Cannabinoids”

Today we interviewed Moav Gafni, Co-founder and Business Development Manager of Cannabotech, a biopharmaceutical company with a focus on the prevention and treatment of cancer, chronic pain and inflammation using botanical elements from medicinal mushrooms and cannabinoids. Everything about Cannabotech is innovative – their wellness products, their personalization technology, their pharmaceutical formulas, and wearable medical device, and even their capital-raising strategy! Moav invites potential strategic partners, research collaboration partners, distributors, and potential investors to reach out at [email protected] Cannabotech website:
Aug 16, 2020 11 min

“Bio-Reactors & Pharma-Grade Full Spectrum Cannabis”

Today we host Dr. Kobi Buxdorf, Founder and CEO of Cannadorf. Kobi reveals to us how Cannadorf is able to sidestep all growing obstacles and manufacture cannabis in a closed biological environment to produce sterile, all-natural, full-spectrum pharma-grade cannabis, with consistently identical profiles every single time. Potential pharma companies or cannabis-based drug developers looking to collaborate are invited to reach out to Kobi at [email protected], Cannadorf website:
Aug 04, 2020 16 min

“Medicalizing Vaporization”

In today’s podcast, we interview Avihu Tamir, Founder, and CEO of Kanabo Research. Kanabo has developed an innovative medical-grade vaporization device that provides metered doses at a standard of safety and quality that physicians can trust. The vaporization device uses only 100% pure extracted pharmaceutical-grade cannabis with no added carriers or additives, with formulations targeted at specific medical indications. Potential distributors, as well as research partners looking to perform clinical trials using Kanabo’s platform, are invited to reach out at [email protected] Kanabo website:
Jul 26, 2020 16 min

"Obesity, Diabetes, Weight Loss and Cannabinoids"

In this episode, Clifton Flack, founder, and CEO of CiiTech, reveals a revolutionary approach to weight loss that’s not centered around appetite suppression. CiiTech is conducting research centered around Fatty Liver Disease, Obesity, and Diabetes. Once patent approval is attained, Ciitech will launch a food supplement version of their unique cannabinoid formulation, while continuing the clinical studies to complete and launch a pharma version of the treatment. Learn about their unique approach and two-pronged mechanism in today’s podcast. Interestingly, though CiiTech currently sells and distributes its line of food supplements in the UK, Clifton has chosen to conduct the research and clinical studies in Israel. In his words: “in addition to Israel’s vast data & experience in medical cannabis research and Israel’s medical innovation mentality, costs of the entire process are significantly more attractive in Israel.” POTENTIAL GLOBAL DISTRIBUTORS interested in distributing the food supplement version, as well as SMART INVESTORS that can add value to the pharma solution are invited to reach out to Clifton at: [email protected]
Jul 19, 2020 20 min

"Nanotechnology and the Blood Brain Barrier"

In this episode, Dr. Orna Dreazen, chairperson of Nextage Cannabis Innovations and Nextar ChemPharma Solutions tells us about breakthrough developments coming out of Nextage. Nextage has developed nanotechnology that enables the penetration of various drugs, including cannabinoids, into the blood brain barrier, exhibiting both safety and efficacy. Dr. Dreazen also describes exciting developments with some of the rare cannabinoids such as CBN. Investors, as well as potential licensing partners, are welcome to reach out to Dr. Dreazen at [email protected] Nextage Cannabis Innovation Center Nextar ChemPharma Solutions
Jul 13, 2020 11 min

“Decoding Biology to Identify New Genetics in Cannabis”

In our new episode, we spoke with Dr. Arnon Heyman, PhD in Plant Biotechnology and CEO of Canonic, a subsidiary of Evogene. Canonic brings new genetics to the cannabis market using a Computational Predictive Biology (CPB) platform which enables them to use Big Data and AI to reach insights within the plant genetics for specific medical indications. Arnon recommends addressing three key industry pains: genetic stability, compound yield and active compounds via the plant genetics. Canonic is a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), the company’s strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations. Canonic has exclusive access to Evogene’s genomic assets and technology for the development of medical Cannabis products. Investors, distributors or growers interested in collaboration are invited to reach Arnon are invited at: [email protected] Canonic’s website:
Jun 17, 2020 16 min

“1 CBD-based patent - 130 potential medical indications”

In today’s episode, we host David Bassa, a serial entrepreneur for the past 30 years in the fields of hi-tech and biotech, with an emphasis on cannabis-based pharma. His company, Stero Biotechs has been issued a CBD-based patent covering over 130 different indications. Stero Biotechs is currently conducting seven different research studies for 7 different indications, two of them in clinical trials (Chron’s disease and Urticaria, also known as hives). Stero Biotechs’s research combats the side effects of steroids, often decreasing or even eliminating steroid use while treating the relevant medical indications. Stero Biotech is an excellent example of Israel’s leading edge in developing Pharma based products, with Israel’s leading HMO as a shareholder, providing access to 5 million patients, 9000 physicians, 14 hospitals and significant cost-efficiency in conducting clinical trials. Stero Biotechs welcomes strategic collaboration opportunities, contact them through: or [email protected]
Jun 03, 2020 15 min

”It’s all about molecules”- innovative pharma products

In this episode, we host Nir Peles, Founder, BOD member and VP Business Development at Cannassure Therapeutics to discuss Cannassure’s cannabis-based pharma products. Cannassure is currently developing innovative & standardized IP protected pharma products with the ‘look and feel’ of pharma products as opposed to plants. These products address topical delivery for skin indications such as psoriasis and rheumatism, fem-tech IUD targeting women’s health issues, and a standardized pill for delivering medical cannabis. One of Israel’s leading cannabis producers, Cannassure produces medical-grade cannabis in a holistic integrated production system that includes an advanced indoor-aeroponic grow facility, a state-of-the-art extraction and processing facility, together with scientifically advanced R&D. Nir welcomes strategic collaboration opportunities, contact him through his LinkedIn profile Cannassure is publicly traded - TASE: CSURE, Visit their website:
May 18, 2020 10 min

The Molecular Method for discovering APIs for specific medical indications

In this episode, we host Prof. Hinanit Koltai of Israel’s Volcan Research Institute to discuss innovation in molecular plant science. Prof. Koltai walks us through the Volcan Institute’s molecular method for discovering the specific combinations of cannabis compounds beneficial in the treatment of medical indications such as inflammatory bowel disease, skin cancer, and colon cancer. Results of the research on skin cancer were recently published in Oncotarget Prof. Koltai’s research team begins with the Volcan Institute's extensive gene bank of cannabis strains from around the world and culminates in clinical trials performed in collaboration with Israel’s physicians and hospitals to validate APIs for each specific medical indication. To collaborate with Prof. Koltai’s research team – contact Hinanit at [email protected]
May 18, 2020 16 min

COVID-19 - A revolutionary treatment approach!

In this episode, Iris Bincovich, CEO of Innocan Pharma shares Innocan’s collaboration with Tel Aviv University to develop a novel, revolutionary approach to treat COVID-19 by using CBD loaded Exosomes. In addition to treating COVID-19, the new drug will target additional central nervous system indications. The goal is to be ready in 2021 to conduct a licensing agreement with a large pharma company. Additionally, Iris shared that Innocan will be launching their new line of CBD topicals, produced in Portugal and the US, during Q2 of this year, including a line of “relief and go” pain-relief topicals as well as a line of cosmetic products. Interested in being a distributor? Contact: [email protected]